Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-trace').style.display = (document.getElementById('cakeErr67f137635f07a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f137635f07a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-code').style.display = (document.getElementById('cakeErr67f137635f07a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-context').style.display = (document.getElementById('cakeErr67f137635f07a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f137635f07a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f137635f07a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26651,
		&#039;title&#039; =&gt; &#039;MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 November, 2014, http://timesofindia.indiatimes.com/india/MNCs-deprive-India-of-vital-drugs/articleshow/45322179.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674689,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26651,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Access to Medicines,Intellectual Property Rights,medicines,Life Saving Drugs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26651,
	&#039;title&#039; =&gt; &#039;MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 November, 2014, http://timesofindia.indiatimes.com/india/MNCs-deprive-India-of-vital-drugs/articleshow/45322179.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674689,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26651
$metaTitle = &#039;LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee&#039;
$metaKeywords = &#039;Access to Healthcare,Access to Medicines,Intellectual Property Rights,medicines,Life Saving Drugs&#039;
$metaDesc = &#039;
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>MNCs deprive India of vital drugs -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><em>MUMBAI: </em>Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.</p><p align="justify">Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.</p><p align="justify">&quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.</p><p align="justify">For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.</p><p align="justify">Novartis's respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline's lapatinib and Novartis's nilotinib - are exorbitantly priced.</p><p align="justify">BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco's Dasanat, priced at Rs 9,000 for a month's treatment as against BMS's Rs 1.66 lakh, has been withdrawn from the market.</p><p align="justify">Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year's treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.</p><p align="justify">&quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.</p><p align="justify">Under the law, if a firm gets a drug patent, it is obligated to locally &quot;work the patent&quot;, that is, make the drug accessible at a reasonable price.</p><p align="justify">Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-trace').style.display = (document.getElementById('cakeErr67f137635f07a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f137635f07a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-code').style.display = (document.getElementById('cakeErr67f137635f07a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-context').style.display = (document.getElementById('cakeErr67f137635f07a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f137635f07a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f137635f07a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26651,
		&#039;title&#039; =&gt; &#039;MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 November, 2014, http://timesofindia.indiatimes.com/india/MNCs-deprive-India-of-vital-drugs/articleshow/45322179.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674689,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26651,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Access to Medicines,Intellectual Property Rights,medicines,Life Saving Drugs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26651,
	&#039;title&#039; =&gt; &#039;MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 November, 2014, http://timesofindia.indiatimes.com/india/MNCs-deprive-India-of-vital-drugs/articleshow/45322179.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674689,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26651
$metaTitle = &#039;LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee&#039;
$metaKeywords = &#039;Access to Healthcare,Access to Medicines,Intellectual Property Rights,medicines,Life Saving Drugs&#039;
$metaDesc = &#039;
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>MNCs deprive India of vital drugs -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><em>MUMBAI: </em>Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.</p><p align="justify">Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.</p><p align="justify">&quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.</p><p align="justify">For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.</p><p align="justify">Novartis's respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline's lapatinib and Novartis's nilotinib - are exorbitantly priced.</p><p align="justify">BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco's Dasanat, priced at Rs 9,000 for a month's treatment as against BMS's Rs 1.66 lakh, has been withdrawn from the market.</p><p align="justify">Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year's treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.</p><p align="justify">&quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.</p><p align="justify">Under the law, if a firm gets a drug patent, it is obligated to locally &quot;work the patent&quot;, that is, make the drug accessible at a reasonable price.</p><p align="justify">Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-trace').style.display = (document.getElementById('cakeErr67f137635f07a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f137635f07a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-code').style.display = (document.getElementById('cakeErr67f137635f07a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f137635f07a-context').style.display = (document.getElementById('cakeErr67f137635f07a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f137635f07a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f137635f07a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26651,
		&#039;title&#039; =&gt; &#039;MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 November, 2014, http://timesofindia.indiatimes.com/india/MNCs-deprive-India-of-vital-drugs/articleshow/45322179.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674689,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26651,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Access to Medicines,Intellectual Property Rights,medicines,Life Saving Drugs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26651,
	&#039;title&#039; =&gt; &#039;MNCs deprive India of vital drugs -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 November, 2014, http://timesofindia.indiatimes.com/india/MNCs-deprive-India-of-vital-drugs/articleshow/45322179.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674689,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26651
$metaTitle = &#039;LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee&#039;
$metaKeywords = &#039;Access to Healthcare,Access to Medicines,Intellectual Property Rights,medicines,Life Saving Drugs&#039;
$metaDesc = &#039;
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&amp;quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis&#039;s respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline&#039;s lapatinib and Novartis&#039;s nilotinib - are exorbitantly priced.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco&#039;s Dasanat, priced at Rs 9,000 for a month&#039;s treatment as against BMS&#039;s Rs 1.66 lakh, has been withdrawn from the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year&#039;s treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&amp;quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the law, if a firm gets a drug patent, it is obligated to locally &amp;quot;work the patent&amp;quot;, that is, make the drug accessible at a reasonable price.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>MNCs deprive India of vital drugs -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><em>MUMBAI: </em>Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.</p><p align="justify">Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.</p><p align="justify">&quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.</p><p align="justify">For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.</p><p align="justify">Novartis's respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline's lapatinib and Novartis's nilotinib - are exorbitantly priced.</p><p align="justify">BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco's Dasanat, priced at Rs 9,000 for a month's treatment as against BMS's Rs 1.66 lakh, has been withdrawn from the market.</p><p align="justify">Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year's treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.</p><p align="justify">&quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.</p><p align="justify">Under the law, if a firm gets a drug patent, it is obligated to locally &quot;work the patent&quot;, that is, make the drug accessible at a reasonable price.</p><p align="justify">Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 26651,
		'title' => 'MNCs deprive India of vital drugs -Rupali Mukherjee',
		'subheading' => '',
		'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
<em>MUMBAI: </em>Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
</p>
<p align="justify">
Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.
</p>
<p align="justify">
&quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.
</p>
<p align="justify">
For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.
</p>
<p align="justify">
Novartis's respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline's lapatinib and Novartis's nilotinib - are exorbitantly priced.
</p>
<p align="justify">
BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco's Dasanat, priced at Rs 9,000 for a month's treatment as against BMS's Rs 1.66 lakh, has been withdrawn from the market.
</p>
<p align="justify">
Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year's treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.
</p>
<p align="justify">
&quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.
</p>
<p align="justify">
Under the law, if a firm gets a drug patent, it is obligated to locally &quot;work the patent&quot;, that is, make the drug accessible at a reasonable price.
</p>
<p align="justify">
Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.
</p>',
		'credit_writer' => 'The Times of India, 30 November, 2014, http://timesofindia.indiatimes.com/india/MNCs-deprive-India-of-vital-drugs/articleshow/45322179.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4674689,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 26651,
	'metaTitle' => 'LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee',
	'metaKeywords' => 'Access to Healthcare,Access to Medicines,Intellectual Property Rights,medicines,Life Saving Drugs',
	'metaDesc' => '
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates...',
	'disp' => '<div align="justify">-The Times of India</div><p align="justify"><em>MUMBAI: </em>Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.</p><p align="justify">Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.</p><p align="justify">&quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.</p><p align="justify">For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.</p><p align="justify">Novartis's respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline's lapatinib and Novartis's nilotinib - are exorbitantly priced.</p><p align="justify">BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco's Dasanat, priced at Rs 9,000 for a month's treatment as against BMS's Rs 1.66 lakh, has been withdrawn from the market.</p><p align="justify">Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year's treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.</p><p align="justify">&quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.</p><p align="justify">Under the law, if a firm gets a drug patent, it is obligated to locally &quot;work the patent&quot;, that is, make the drug accessible at a reasonable price.</p><p align="justify">Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 26651,
	'title' => 'MNCs deprive India of vital drugs -Rupali Mukherjee',
	'subheading' => '',
	'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
<em>MUMBAI: </em>Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
</p>
<p align="justify">
Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.
</p>
<p align="justify">
&quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.
</p>
<p align="justify">
For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.
</p>
<p align="justify">
Novartis's respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline's lapatinib and Novartis's nilotinib - are exorbitantly priced.
</p>
<p align="justify">
BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco's Dasanat, priced at Rs 9,000 for a month's treatment as against BMS's Rs 1.66 lakh, has been withdrawn from the market.
</p>
<p align="justify">
Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year's treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.
</p>
<p align="justify">
&quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.
</p>
<p align="justify">
Under the law, if a firm gets a drug patent, it is obligated to locally &quot;work the patent&quot;, that is, make the drug accessible at a reasonable price.
</p>
<p align="justify">
Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.
</p>',
	'credit_writer' => 'The Times of India, 30 November, 2014, http://timesofindia.indiatimes.com/india/MNCs-deprive-India-of-vital-drugs/articleshow/45322179.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'mncs-deprive-india-of-vital-drugs-rupali-mukherjee-4674689',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4674689,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 26651
$metaTitle = 'LATEST NEWS UPDATES | MNCs deprive India of vital drugs -Rupali Mukherjee'
$metaKeywords = 'Access to Healthcare,Access to Medicines,Intellectual Property Rights,medicines,Life Saving Drugs'
$metaDesc = '
-The Times of India


MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.


Corporates...'
$disp = '<div align="justify">-The Times of India</div><p align="justify"><em>MUMBAI: </em>Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.</p><p align="justify">Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB.</p><p align="justify">&quot;MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow,&quot; a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world.</p><p align="justify">For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world.</p><p align="justify">Novartis's respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline's lapatinib and Novartis's nilotinib - are exorbitantly priced.</p><p align="justify">BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco's Dasanat, priced at Rs 9,000 for a month's treatment as against BMS's Rs 1.66 lakh, has been withdrawn from the market.</p><p align="justify">Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year's treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively.</p><p align="justify">&quot;Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented,&quot; Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said.</p><p align="justify">Under the law, if a firm gets a drug patent, it is obligated to locally &quot;work the patent&quot;, that is, make the drug accessible at a reasonable price.</p><p align="justify">Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

MNCs deprive India of vital drugs -Rupali Mukherjee

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV, hepatitis C and TB. "MNCs keep prices of their breakthrough treatments unaffordable for many in India, and in certain cases delay the launch here, worried that the country may become a good example of reference pricing for others to follow," a public health activist said. These MNCs target the more lucrative mature markets as against treating those in the developing world. For instance, a scrutiny of regulatory documents made available to TOI by legal experts reveal how Otsuka, which has a patent for delamanid since December 2011, has not imported even a single pack into India yet. The drug, used to treat multi-drug-resistant (MDR) TB, has not been imported in enough quantities even for the mandated local trials. This, even as WHO estimates that India is home to the most number of MDR-TB patients in the world. Novartis's respiratory medicine Onbrez is another example. Similarly, affordable versions of anti-cancer drugs such as sunitinib and dasatinib have been taken off the retail shelves in accordance with the patent law. Those made by MNCs - GlaxoSmithKline's lapatinib and Novartis's nilotinib - are exorbitantly priced. BMS, for example, got a patent for dasatinib in November 2006 and has effectively blocked generic competition, filing infringement suits in the Delhi HC against Hyderabad-based Natco Pharma. Natco's Dasanat, priced at Rs 9,000 for a month's treatment as against BMS's Rs 1.66 lakh, has been withdrawn from the market. Significantly, data submitted by BMS to the government for its dasatinib version, Sprycel, shows that the maximum number of patients that could have been provided a single year's treatment for CML in 2011-12 and 2012-13 was 300 and 508, respectively. "Nearly 10 years have passed since India introduced product patenting and slowly (the number of) medicines that are patented are growing. It is critical that provisions in the Patent Act are fully and properly implemented," Leena Menghaney, South Asia manager for global humanitarian organization Medecins Sans Frontieres said. Under the law, if a firm gets a drug patent, it is obligated to locally "work the patent", that is, make the drug accessible at a reasonable price. Recently, generic drugmaker Cipla asked the government to revoke five patents held by Novartis on Onbrez (indacaterol) and launched a cheaper version. It alleged that Novartis had patents on the medicine since 2008 but has not produced it in the country. Instead, Cipla alleged, Novartis had imported negligible quantities of the drug, leading to a shortage in the market.